Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05432518
Other study ID # GBM-2022
Secondary ID
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date June 27, 2023
Est. completion date December 1, 2027

Study information

Verified date May 2024
Source AHS Cancer Control Alberta
Contact Paula de Robles, MD
Phone 403-944-8386
Email paula.derobles@albertahealthservices.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their recurrent GBM tumor resected at the time of surgery. It will be aimed to gather preliminary information on the study intervention and the feasibility of conducting a full-scale trial.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date December 1, 2027
Est. primary completion date July 1, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Study participant has provided informed consent prior to initiation of any study specific activities/procedures. 2. Adult participants, male and female, aged =18 who have a pathologically confirmed IDH-wild type glioblastoma, with first or second progression of the tumor, after initial treatment with radiation therapy and temozolomide. 3. Recurrence is amenable to resection. 4. Performance status: ECOG =2. 5. Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes. 6. Patients of childbearing potential must adhere to the contraception requirement from screening throughout the study period up to 180 days after the last dose of study intervention. Women/men of childbearing potential must have agreed to use two highly effective contraceptive methods. In addition to routine contraceptive methods such as condom use, oral contraceptive, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures. Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard. 7. Able to undergo brain MRIs. 8. Females must not be breastfeeding, throughout the study period up to 180 days after the last dose of study intervention. 9. Male patients should agree to not donate sperm during the study for at least 6 months until discontinuation of study drug. Exclusion Criteria: 1. Patients with history of abnormal left ventricular ejection fraction (LVEF= 45%). 2. Pregnant, breast-feeding, unwilling/unable to comply with contraception requirements. 3. Patients unable to consent. 4. Abnormal (grade =2 CTCAE, version 5.0) laboratory values for hematology, renal, and liver function including: 1. Hemoglobin <10, 2. Neutrophils <1.5, 3. Platelets <75, 4. ALT/AST >3x ULN, 5. Bilirubin >1.5 x ULN, 6. eGFR <60 5. Patients with significant or recent gastrointestinal disorders with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption or severe diarrhea of any etiology) must be excluded from the clinical trial (Afatanib is not recommended in this patient population). 6. Patients with a history of ILD (interstitial lung disease) must be excluded. 7. Patients with severe hepatic impairment (Child Pugh C). 8. A significantly abnormal ECG (baseline QTcF interval > 450 msec). 9. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. 10. Patients with known pre-existing pleural effusion. 11. Active hepatitis B or C infection and/or known history of HIV infection. 12. Has known psychiatric or substance abuse disorders that would interfere with compliance with the requirements of the trial. 13. Subject will not be available for protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge. 14. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks from the date of signing the informed consent form. 15. Patients who are hypersensitive to any ingredients in the formulation of the study drugs or their excipients. 16. Patients receiving active treatment for a different cancer. 17. If recent bacterial infection, patients need to have completed antibiotic course prior to commencing study drug. 18. If recent COVID-19 infection, patients must have recovered from it prior to commencing study drug. 19. Patients on strong CYP3A/p-gp inducers (for example, carbamazepine and phenytoin).

Study Design


Intervention

Drug:
Afatinib
Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.
Dasatinib
Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.
Palbociclib
Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.
Everolimus
Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.
Olaparib
Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.

Locations

Country Name City State
Canada Tom Baker Cancer Centre Calgary Alberta

Sponsors (2)

Lead Sponsor Collaborator
AHS Cancer Control Alberta Tom Baker Cancer Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Genomic and expression profiling Number of patients for whom we were able to have genomic and expression profiling on their tissue samples and organoids From date of initial consent to participate to end of follow up period (24 months)
Other Organoid drug response Number of patients for whom we can determine organoid drug response to study drugs From date of initial consent to participate to end of follow up period (24 months)
Other Correlation of genomic and expression profiling of tissue and organoid with the organoid's best drug response Number of patients for whom the genomic and expression profiling of their tissue and organoid directly correlates to the organoid's best drug response From date of initial consent to participate to end of follow up period (24 months)
Primary Success rate of personalized GBM treatment based on molecular characterization of recurrent tumor Percentage of patients, interested in participating, consented and detected with target mutations and completed the treatment with one of the 5 study drugs From date of initial consent to participate to the end of follow up period (24 months)
Secondary Overall survival (OS) OS is calculated as the period from the day of starting administration of the study drug to the day of death from any cause. From date of study drug administration until date of death from any cause (approximately 24 months)
Secondary Progression free survival (PFS) PFS is calculated as the period from the day of starting administration of the study drug to the date that disease progression is confirmed by radiographic assessment and RANO criteria. From date of study drug administration until date of radiographic confirmed progression (approximately 2 years)
Secondary Quality of Life (QoL) EORTC QLQ-C30 The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented. Baseline until the end of treatment
Secondary Quality of Life (QoL) EORTC QLQ BN-20 Quality of Life measures are recorded according to EORTC QLQ BN-20 module, which is validated for brain tumor patients and measured as a unit of scale. This is a standard tool for assessing patient reported quality of Life along time during treatment. EORTC QLQ BN-20 (BN-20): 4 scales comprised of multiple items and 7 single items. All items are rated on a 4-point Likert-type scale, 1=not at all' to 4=very much, and linearly transformed to a 0-100 scale, higher scores indicating more severe symptoms.
The scores across all time points were averaged to obtain the mean.
Baseline until the end of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05664243 - A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Recruiting NCT05635734 - Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Terminated NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Active, not recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Completed NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02206230 - Trial of Hypofractionated Radiation Therapy for Glioblastoma Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Withdrawn NCT02876003 - Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma Phase 2